We use cookies to store user settings and preferences on this site. We do not preserve any personal data in cookies.

Kidney Organoid Models as Research Tools

The collection of technologies offers a variety of hPSC-derived kidney organoid models that accurately recapitulate kidney function and disease. The robust platform is ready for immediate use in high-growth research areas such as kidney tissue regeneration studies, drug candidate screening, and renal pathophysiology research.
Technology No. BDP 7861

What is the Problem?

The use of organoids, which are collections of cells in vitro that resemble a bodily organ in structure and function, has been limited in drug development and high-throughput experimentation due to a lack of scalable methods for manufacturing organoid cultures.

What is the Solution?

The present technologies provide a variety of kidney organoid models that accurately recapitulate kidney function and disease, allowing for the study of kidney differentiation and pathologies, as well as therapeutic discovery. The innovation includes a method for fully automated differentiation of kidney organoids from human pluripotent stem cells (hPSCs) in 96-well and 384-well formats. It also offers a highly specific hPSC-derived polycystic kidney disease (PKD) model, a CRISPR-edited hPSC model for autosomal dominant PKD, a SARS-CoV-2 kidney organoid model, a platform to study the effects of cilia on tissue differentiation capacity of hPSC cells, and methods to subject PKD-on-a-chip microphysiological systems to fluid shear stress.

What is the Competitive Advantage?

The competitive advantage of these innovations lies in their ability to provide a range of highly accurate kidney organoid models that can be used for various applications, such as nephrotoxicology screening, patient-specific regenerative medicine, and high-throughput therapeutic discovery. By offering scalable methods for manufacturing organoid cultures, these technologies can help accelerate research and development in the field of nephrology and contribute to the growing organoids market.

Patent Information:

US20210290632A1

WO2023060234A1

Questions about this technology?